sulfamethoxazole brands

17 registered brands containing sulfamethoxazole in Ghana.

sulfamethoxazole

PubChem CID 5329

Molecular formula: C10H11N3O3S

Sulfamethoxazole is a sulfonamide that inhibits bacterial dihydrofolic acid synthesis due to its structural similarity to an endogenous substrate, para-aminobenzoic acid (PABA). Most bacteria meet their need for folic acid by synthesizing it from PABA, as opposed to Animalia that require exogenous folic acid sources. Sulfamethoxazole competitively inhibits dihydropteroate synthase, the enzyme responsible for bacterial conversion of PABA to dihydrofolic acid. Inhibition of this pathway prevents the synthesis of tetrahydrofolate and, ultimately, the synthesis of bacterial purines and DNA, resulting in a bacteriostatic effect. Sulfonamides are usually bacteriostatic in action. Sulfonamides interfere with the utilization of p-aminobenzoic acid (PABA) in the biosynthesis of tetrahydrofolic acid (the reduced form of folic acid) cofactors in susceptible bacteria. Sulfonamides are structural analogs of PABA and appear to interfere with PABA utilization by competitively inhibiting the enzyme dihydropteroate synthase, which catalyzes the formation of dihydropteroic acid (a precursor of tetrahydrofolic acid) from PABA and pteridine; however, other mechanism(s) affecting the biosynthetic pathway also may be involved. Compounds such as pyrimethamine and trimethoprim, which block later stages in the synthesis of folic acid, act synergistically with sulfonamides. Only microorganisms that synthesize their own folic acid are inhibited by sulfonamides; animal cells and bacteria which are capable of utilizing folic acid precursors or preformed folic acid are not affected by these drugs. The antibacterial activity of the sulfonamides is reportedly decreased in the presence of blood or purulent body exudates. /Sulfonamides/ /Sulfonamides inhibit bacterial growth by preventing para-aminobenzoic acid (PABA) from being incorporated/ into dihydropteroic acid, the immediate precursor of folic acid. Sensitive microorganisms are those that must synthesize their own folic acid; bacteria that can utilize preformed folate are not affected. Bacteriostasis induced by sulfonamides is counteracted by PABA competitively. Sulfonamides do not affect mammalian cells by this mechanism, since they require preformed folic acid and cannot synthesize it. /Sulfonamides/ Sulfonamides are broad-spectrum, bacteriostatic anti-infectives. They are structural analogs of para-aminobenzoic acid and competively inhibit a bacterial enzyme, dihydropteroate synthetase, that is responsible for incorporation of para-aminobenzoic acid into dihydrofolic acid. This blocks the synthesis of dihydrofolic acid and decreases the amount of metabolically active tetrahydrofolic acid, a cofactor for the synthesis of purines, thymidine, and DNA. /Sulfonamides/ The hydroxylamine and nitroso metabolites formed by N4-oxidation of sulfonamides are thought to be involved in the pathogenesis of idiosyncratic reactions to this class of drugs. Idiosyncratic reactions to sulfonamides are characterized by multisystemic toxicity, including hepatitis, nephritis, dermatitis, and blood dyscrasias (aplastic anemia, agranulocytosis). Previously it has been shown that cytochrome p-450 in the liver metabolizes sulfamethoxazole to its hydroxylamine metabolite. In this paper the N4-oxidation of sulfamethoxazole by activated monocytes and neutrophils (human and canine) to form sulfamethoxazole hydroxylamine and nitrosulfamethoxazole is reported. The presumed nitroso intermediate was not detected. Purified myeloperoxidase and prostaglandin H synthase were also capable of mediating the oxidation of sulfamethoxazole. The present studies suggest that myeloperoxidase is responsible for the observed oxidation by phagocytic cells. Oxidation by neutrophils may play a role in agranulocytosis, and oxidation by monocytes may facilitate antigen presentation. Extrahepatic bioactivation of sulfonamides by peroxidases in phagocytic cells and other tissues may be important in determining the range of adverse reactions to sulfonamides

Source: PubChem (NCBI) ยท compound 5329

Product Manufacturer Status Country
CO-TRIMOXAZOLE
ORAL SUSPENSION
M&g Pharmaceuticals Valid Ghana
CO-TRIMOXAZOLE TABLETS (Each tablet contains Sulphamethoxazole B.P/Trimethoprim 400mg/80mg)
Sulphamethoxazole B.P/Trimethoprim
Entrance Pharmaceuticals Valid Ghana
CO-TRIMOXAZOLE TABLETS
Sulfamethoxazole BP/ Trimethoprim BP
M&g Pharmaceuticals Valid Ghana
CO-TRIMOXAZOLE TABLETS Letap Pharmaceuticals Valid Ghana
CO-TRIMOXAZOLE TABLETS
TABLET
Phyto-riker Pharmaceuticals Valid Ghana
CO-TRIMOXAZOLE TABLETS (Each tablet contains Sulfamethoxazole BP/ Trimethoprim BP 340mg/50mg)
TABLETS
Phyto-Riker Pharmaceuticals Valid Ghana
CONTRI-480 TABLETS
Sulfamethoxazole BP/ Trimethoprim BP
Oa&j Phamaceuticals Ltd Valid Ghana
DEPTRIN 480 TABLETS
Tablet Oral
Danadams Pharmaceutical Industry Valid Ghana
ESCOTRIM TABLETS
TABLET
Eskay Therapeutics Valid Ghana
GLODRIL SUSPENSION (SULPHAMETHOXAZOLE 200MG+TRIMETHOPRIM 80MG)
SUSPENSION
New Global Pharmaceuticals 3 months to expiry Ghana
GLODRIL TABLETS (SULPHAMETHOXAZOLE 200MG+TRIMETHOPRIM 80MG)
TABLETS
New Global Pharmaceuticals 3 months to expiry Ghana
ISOKIN SUSPENSION
ORAL SUSPENSION
Kinapharma 3 months to expiry Ghana
ISOKIN TABLETS
TABLETS
Kinapharma Valid Ghana
NESTRIM 240 SUSPENSION (Each 5ml contains Sulphamethoxazole B.P/Trimethoprim 200mg/40mg)
Sulphamethoxazole B.P/Trimethoprim
Ernest Chemists Valid Ghana
NESTRIM 480 TABLETS (Each tablet contains Sulphamethoxazole B.P/Trimethoprim 400mg/80mg)
Sulphamethoxazole B.P/Trimethoprim
Ernest Chemists Valid Ghana
SEPTREX SUSPENSION
Sulfamethoxazole BP/ Trimethoprim BP
Phyto-Riker Pharmaceuticals Valid Ghana
T.S. SOL SOLUTION (TRIMETHOPRIM+SULFAMETHOXAZOLE -20MG+80MG)
SOLUTION
Dopharma International Valid Ghana